Condition: Poliomyelitis · Sponsor: PATH
The purpose of this clinical trial is to assess the safety and tolerability (primary objective), immunogenicity (primary and secondary objectives), fecal shedding of vaccine viruses (secondary objective) and the potential for neurovirulence of shed virus (secondary objective) of a novel oral polio type 3 vaccine, nOPV3, as compared to Sabin monovalent type 3 vaccine controls (mOPV3), in healthy young children (192 subjects), infants (860 subjects), and neonates (480 subjects).
This description comes directly from the study's public registry record.
Xavier Saez-Llorens, MD · +507 203-9760 · xavier.saez-llorens@cevaxin.com
Always discuss trial participation with your own doctor first.
| Cevaxin - 24 de Diciembre | Panama City, Panama | Recruiting |
| Cevaxin - Chorrera | Panama City, Panama | Recruiting |
| Cevaxin-- Avenida Mexico | Panama City, Panama | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05654467